PeriphaGen

Headquarters

Pittsburgh, PA

PeriphaGen is a biopharmaceutical company focused on the development of herpes simplex virus type I (HSV-1) as a gene therapy vector for neurologic disease. The company has developed a replication defective HSV-1 vector platform called 'Neuronal Therapeutics' (NET) for delivery of tissue specific gene expression in sensory neurons from a simple skin administration. PeriphaGen's lead product, PGN-503, is designed to prevent or treat peripheral neuropathy in patients receiving chemotherapy.

• Krystal Biotech, IncKrystal Biotech, Inc. is a commercial-stage biotechnology company developing and commercializing genetic medicines for patients with rare diseases using a proprietary redosable HSV-1 vector platform. The company operates integrated manufacturing facilities and has an approved gene therapy product, VYJUVEK, for dystrophic epidermolysis bullosa.325412PITTSBURGH, PA
• Neuropathix, IncNeuropathix, Inc. is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthrough therapeutics targeting inflammation to treat patients with significant unmet medical needs. The company's lead candidate is KLS-13019, a patented, non-opioid cannabinoid derivative for neuropathic pain.DOYLESTOWN, PA
• GeneLancet BiosciencesGeneLancet Biosciences is a precise gene editing company that develops proprietary LgRNA technology for scalable, high-purity guide RNA production and non-immunogenic STAR editors for therapeutic applications. The company focuses on cures for neurodegenerative disorders, cancers, and chronic viral infections.541714DOYLESTOWN, PA
• Evrys BioEvrys Bio is a privately held biotech focused on developing first-in-class antiviral therapies that target host cell sirtuin proteins to treat a broad spectrum of viruses and prevent drug resistance. The company is developing allosteric small molecule SIRT2 modulators and has a clinic-ready asset (EV-100) poised for proof-of-concept data.DOYLESTOWN, PA